SAIB Stabilized Amorphous Drug Solutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly water-soluble drugs face challenges with low oral bioavailability due to high lipophilicity and poor aqueous solubility, and existing methods to enhance solubility and stability, such as amorphization, are not sufficient as they are thermodynamically unstable and prone to crystallization under varying conditions.
Innovation Solution
Formulating poorly water-soluble drugs with sucrose acetate isobutyrate (SAIB) to create stable amorphous solid solutions or dispersions, where the drug is in a molecular or amorphous state within the SAIB matrix, which maintains stability against crystallization at elevated temperatures and humidity, and can be formulated into oral dosage forms with improved dissolution rates and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If amorphous form is used to increase solubility and dissolution rate, then dissolution rate and extent are improved, but thermodynamic stability deteriorates leading to crystallization
Solution Approach 1:
A hydrophilic polymer is introduced as an intermediary substance that stabilizes the amorphous drug form. The polymer acts as a mediator between the amorphous drug molecules and the environment, preventing crystallization while maintaining the high dissolution rate characteristics of the amorphous state. This resolves the contradiction by providing a stable carrier system that preserves both improved dissolution performance and thermodynamic stability.
Solution Approach 2:
The invention creates a composite material system consisting of the amorphous drug combined with a hydrophilic polymer matrix. This composite structure leverages the high solubility and dissolution rate of the amorphous drug while the polymer matrix provides structural stability and prevents crystallization. The composite approach allows simultaneous achievement of improved dissolution kinetics and enhanced stability.
2Stability of the object's composition
If hydrophilic polymers are added to increase stability of amorphous drug, then thermodynamic stability is improved, but dissolution rate may be reduced due to polymer presence
Solution Approach 1:
The invention optimizes the concentration and molecular weight parameters of the hydrophilic polymer to achieve the desired balance between stability and dissolution rate. By carefully controlling these parameters, the polymer provides sufficient stabilization against crystallization while maintaining adequate drug dissolution performance. This parameter optimization resolves the contradiction between stability improvement and potential dissolution rate reduction.
3Quantity of substance
If amorphous form is used to overcome high lattice energy, then apparent solubility is enhanced, but crystallization occurs under exaggerated temperature and humidity conditions
Solution Approach 1:
The hydrophilic polymer serves as a protective intermediary that shields the amorphous drug from environmental factors such as temperature and humidity variations. This intermediary layer prevents direct interaction between the unstable amorphous drug and harsh storage conditions, thereby maintaining apparent solubility enhancements while ensuring reliability under varying storage conditions.
Solution Approach 2:
The hydrophilic polymer forms a flexible protective matrix or shell around the amorphous drug molecules. This protective structure acts as a barrier that prevents crystallization nucleation and growth under exaggerated temperature and humidity conditions, while maintaining the high apparent solubility characteristics of the amorphous form. The flexible matrix adapts to different storage conditions without compromising drug stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of SAIB stabilizes amorphous drugs, enhancing their dissolution rates and bioavailability by maintaining them in an amorphous state, leading to higher serum concentrations and area under the curve (AUC) compared to equivalent formulations without SAIB, while maintaining stability over time and under different storage conditions.
Implementation Method 1
In amorphization, a crystalline drug is transformed to amorphous form. Amorphous form is, by definition, a non-crystalline material which possesses no long-range order.
Implementation Method 2
The transition from the glassy to the rubbery state is characterized by a temperature called the glass-transition temperature (Tg).
Implementation Method 3
heating the SAIB to a temperature sufficient to dissolve the PSD and for the PSD to exist in the molecular or amorphous state in the SAIB
Implementation Method 4
cooling the mixture to form a pharmaceutical composition comprising an amorphous solid solution or an amorphous solid dispersion
Data Source
AI summary
Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.